<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03475251</url>
  </required_header>
  <id_info>
    <org_study_id>CS1003-101</org_study_id>
    <secondary_id>ACTRN12618000382279</secondary_id>
    <nct_id>NCT03475251</nct_id>
  </id_info>
  <brief_title>A Study of CS1003 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CStone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CStone Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment
      effect of a new drug known as CS1003 in patients with advanced tumors.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From the day of first dose to 30 days after last dose of CS1003</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>From the day of first dose to 30 days after last dose of CS1003</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>From the day of first dose to 30 days after last dose of CS1003</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>From the day of first dose to 30 days after last dose of CS1003</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>From the day of first dose to 30 days after last dose of CS1003</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease assessment by CT/MRI scan</measure>
    <time_frame>To be performed every 9 weeks during treatment period (up to 2 years) and within 30 days after last dose of CS1003</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-CS1003 antibody</measure>
    <time_frame>From the day of first dose to 30 days after last dose of CS1003</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>CS1003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CS1003</intervention_name>
    <description>In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, patients will be assigned to different groups based on their tumor type.</description>
    <arm_group_label>CS1003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have histologically or cytologically confirmed advanced or metastatic
             solid tumor and have progressed, are intolerant to, refuse to accept or do not have
             access to standard therapy.

          2. ECOG performance status of 0 or 1.

          3. Subjects with evaluable but non-measurable lesion are eligible for Phase Ia. Subjects
             must have at least one measurable lesion per RECIST Version 1.1 to be eligible for
             Phase Ib.

          4. Archived tumor tissue samples need to be collected, or subjects consent to undergo
             pre-treatment biopsy if archived sample is not available.

          5. Life expectancy ≥ 3 months.

          6. Subject must have adequate organ function.

          7. Use of effective contraception (males and females).

        Exclusion Criteria:

          1. Subjects with known symptomatic or untreated brain metastasis or other CNS metastasis.

          2. Subjects with active autoimmune diseases or history of autoimmune diseases.

          3. Subjects who have to receive glucocorticoids (prednisone at &gt; 10 mg/day or equivalent)
             or other immunosuppression within 14 days prior to the first dose of CS1003.

          4. Subjects with other malignant tumor(s) in the past 2 years are not eligible for Phase
             Ib, except for those with basal cell carcinoma, in situ breast cancer and cervical
             carcinoma in situ who have undergone radical treatment.

          5. Subjects who have received any immune checkpoint treatment, including PD-1, PD-L1,
             etc.

          6. Receipt of chemotherapy, targeted therapy, or any other anti-cancer systemic treatment
             within 2 weeks prior to the first dose of CS1003.

          7. Receipt of major surgical procedure or wide field of radiation within 28 days prior to
             the first dose of CS1003, local radiotherapy within 14 days prior to the first dose of
             CS1003, or radioactive agents within 56 days before the first dose of CS1003.

          8. Receipt of Chinese herbal medicine or Chinese prepared medicine within 7 days prior to
             the first dose of CS1003.

          9. Receipt of live vaccine within 28 days prior to the first dose of CS1003.

         10. History of interstitial lung disease or non-infectious pneumonitis, except for those
             induced by radiation therapies.

         11. History of HIV infection.

         12. Subjects with active Hepatitis B and C infection (HBV DNA ≥ 1000 cps/mL or 200 IU/mL)
             requiring therapy.

         13. Subjects with active infection of tuberculosis.

         14. Subjects with signs or symptoms of any active infection requiring systemic therapy.

         15. History of organ transplantation.

         16. Unresolved toxicities from prior anti-cancer therapy.

         17. History of any irAE of Grade ≥ 3.

         18. History of uncontrolled allergic asthma and serious hypersensitive reaction to
             monoclonal antibodies.

         19. History of alcoholism or drugs abuse.

         20. Subjects with major cardiovascular diseases.

         21. Any condition that, in the opinion of the investigator or sponsor, would jeopardize
             compliance.

        For more information regarding trial participation, please contact at
        cstonera@cstonepharma.com
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Queenie Yu</last_name>
    <role>Study Director</role>
    <affiliation>CStone Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Queenie Yu</last_name>
    <phone>+86 21 6109 7678</phone>
    <email>cstonera@cstonepharma.com</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2018</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

